•
Jun 30, 2021

Tenet Healthcare Q2 2021 Earnings Report

Tenet Healthcare's Q2 2021 results reflected long-term strategy and transformation progress.

Key Takeaways

Tenet Healthcare reported a strong second quarter in 2021, with net income from continuing operations available to common shareholders of $120 million, or $1.11 per diluted share, compared to $88 million, or $0.83 per diluted share, in Q2 2020. Adjusted EBITDA was $834 million, and adjusted diluted earnings per share from continuing operations were $1.59. The company raised its full-year 2021 financial guidance, citing continued growth, operational improvements, and grant income.

Net income from continuing operations available to common shareholders in Q2 2021 was $120 million, compared to $88 million in Q2 2020.

Consolidated Adjusted EBITDA in Q2 2021 was $834 million versus $732 million in Q2 2020.

Diluted earnings per share from continuing operations available to common shareholders in Q2 2021 was $1.11 compared to $0.83 in Q2 2020; Adjusted diluted earnings per share from continuing operations of $1.59 in Q2 2021 compared to $1.26 in Q2 2020.

The FY 2021 Outlook was increased due to continued growth and operational improvements as well as grant income.

Total Revenue
$4.95B
Previous year: $3.65B
+35.8%
EPS
$1.12
Previous year: $0.84
+33.3%
Admissions growth
13.7%
Gross Profit
$4.1B
Previous year: $3.04B
+34.8%
Cash and Equivalents
$2.19B
Previous year: $3.51B
-37.6%
Free Cash Flow
$123M
Previous year: $2.13B
-94.2%
Total Assets
$26.6B
Previous year: $26.3B
+1.2%

Tenet Healthcare

Tenet Healthcare

Tenet Healthcare Revenue by Segment

Forward Guidance

Tenet Healthcare raised its full-year 2021 outlook, expecting net operating revenues between $19.250 billion and $19.650 billion, Adjusted EBITDA between $3.150 billion and $3.250 billion, and Adjusted diluted earnings per share between $5.23 and $5.73.

Positive Outlook

  • Net operating revenues are expected to be between $19,250 million and $19,650 million.
  • Adjusted EBITDA is projected to be between $3,150 million and $3,250 million.
  • Diluted income per common share from continuing operations is anticipated to be between $6.25 and $7.17.
  • Adjusted net income from continuing operations is expected to be between $570 million and $625 million.
  • Adjusted diluted earnings per share from continuing operations are projected to be between $5.23 and $5.73.

Challenges Ahead

  • Interest expense is expected to be between $935 million and $945 million.
  • Depreciation and amortization are projected to be between $850 million and $870 million.
  • Capital expenditures are estimated to be between $700 million and $750 million.
  • NCI cash distributions are expected to be between $460 million and $480 million.
  • Effective tax rate is projected to be ~17%.

Revenue & Expenses

Visualization of income flow from segment revenue to net income